Back to News
Market Impact: 0.05
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Source: globenewswire.com
Healthcare & BiotechManagement & Governance
Tempest Therapeutics, a clinical-stage developer of in vivo CAR-T therapies for cancer and autoimmune disease, issued an announcement referencing Matt Angel, Ph.D. The provided article text is incomplete and does not disclose the nature of the announcement, financial terms, clinical data, or expected business impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
TPST0.10
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic
- ‘It wasn’t me, and I don’t think it was Elon’: Trump and his cabinet send mixed messages about what led to Ukraine’s Starshield interruptions